Multiple myeloma
Robert A. Kyle, S. Vincent Rajkumar · Blood · 2008
Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present. The evolution of drug therapy and stem-cell transplantation for the treatment of myeloma, as well as the development of new agents, is discussed. We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies.
Cited by 855 works. doi:10.1182/blood-2007-10-078022 Open-access PDF
Authors
References
- Méthode permettant l'étude conjuguée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines. Application au sérum sanguin
- A new apparatus for electrophoretic analysis of colloidal mixtures
- ELECTROPHORESIS OF PROTEINS ON FILTER PAPER
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
- Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
- The ubiquitin-proteasome proteolytic pathway
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
- AN ELECTROPHORETIC STUDY OF IMMUNE SERA AND PURIFIED ANTIBODY PREPARATIONS
- Thalidomide is an inhibitor of angiogenesis.
- A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma